Hansa Biopharma AB (publ)
HNSBF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$328.1M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $328.10 Million |
|---|---|
| Enterprise Value | $453.03 Million |
| Earnings per Share | $-6.55 |
| Beta | 1.58 |
| Outstanding Shares | 99,756,410 |
Return
| Return on Equity | 116.67% |
|---|---|
| Return on Assets | -41.51% |
| Return on Invested Capital | -60.17% |
Valuation & Multiples
| P/E Ratio | -5.93 |
|---|---|
| PEG | -27.69 |
| Price to Sales | 1.1 |
| Price to Book Ratio | -0.47 |
| Enterprise Value to Revenue | 1.5 |
| Enterprise Value to EBIT | -0.77 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 3.23 |
| Debt to Equity | -2.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 11, 2026
EPS
-$0.17
Est. -$0.14Revenue
$14.23 M
Est. $7.17 MNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
-$0.09
Consensus analyst estimateRevenue Estimate
$14.79 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Hansa Biopharma AB (publ)
131 employees
CEO: Renée Julie Elisabet Aguiar-Lucander
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare...